Cathie Wood’s 2022 Portfolio: 5 Small-Cap Stock Picks

2. Fate Therapeutics, Inc. (NASDAQ:FATE)

ARK Investment Management’s 13 Portfolio: 1.77% 

ARK Investment Management’s Stake Value: $426.01 million

Number of Hedge Fund Holders: 31

Market Cap: $2.11 billion

Biopharmaceutical firm Fate Therapeutics, Inc. (NASDAQ:FATE) is up next on the list of Cathie Wood’s top small-cap stock picks. The firm develops programmed cellular immunotherapies for cancer and immune disorders. Regulatory data for the first quarter of 2022 showed that Cathie Wood owned 10.98 million shares of the firm priced at $426 million, representing 1.77% of her overall portfolio.

Truist analyst Robyn Karnauskas on April 13 maintained a ‘Buy’ rating on Fate Therapeutics, Inc. (NASDAQ:FATE) shares, and lowered the price target to $75 from $125.

As of the end of the fourth quarter, 31 hedge funds owned stakes in Fate Therapeutics, Inc. (NASDAQ:FATE), with a combined worth of $1.77 billion. This is down from 36 hedge funds holding $2.1 billion worth of positions in the firm a quarter earlier.

Fate Therapeutics, Inc. (NASDAQ:FATE) reported its first quarter earnings on May 4, and EPS was recorded at-$0.68, beating estimates by $0.06. Revenue of $18.4 million for the quarter was also above analysts’ forecasts by $9.4 million, and registered an uptick of 65.27% from the year-ago quarter.